CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
4 Min Read
MONTREAL/TORONTO (Reuters) - Medical companies and shippers in Canada are racing to transport time-sensitive radiochemical materials used to treat cancer, as a pandemic-induced drop in passenger flights has narrowed transportation options and created cargo delays.
FILE PHOTO: An American Airlines cargo plane is unloaded at Philadelphia International Airport in Philadelphia, Pennsylvania, U.S., December 4, 2020. REUTERS/Rachel Wisniewski/File Photo
Half of air cargo normally travels in the belly of passenger jets rather than dedicated freighters. But flight cancellations as traffic plummeted during the pandemic have left some companies scrambling to ship treatments that decay over time, pushing up overall transportation costs.
(1)
TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium - 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed. CanProbe s NET clinical program has helped many patients in Ontario who previously had no other options for treatment, says Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. We are excited to extend access to this treatment by leveraging CanProbe s intellectual property to seek regulatory approvals, with the
POINT Biopharma
POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment
POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment
TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed.
MONTREAL/TORONTO (REUTERS) - Medical companies and shippers in Canada are racing to transport time-sensitive radiochemical materials used to treat cancer, as a pandemic-induced drop in passenger flights has narrowed transportation options and created cargo delays.
Half of air cargo normally travels in the belly of passenger jets rather than dedicated freighters. But flight cancellations as traffic plummeted during the pandemic have left some companies scrambling to ship treatments that decay over time, pushing up overall transportation costs.
Before the pandemic, the McMaster Nuclear Reactor in the Canadian province of Ontario could ship its iodine-125 isotope anywhere in a couple of days.